Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.17 (
lysozyme
)
21,489
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have previously shown that antigens complexed to the receptor-recognized form of alpha(2)-macroglobulin (alpha(2)M*) demonstrate enhanced immune responsiveness mediated by the low density lipoprotein receptor-related protein LRP/
CD91
. Recently, we developed a proteinase-independent method to covalently bind antigens to alpha(2)M*. Given the potential applications of this chemistry, we analyzed the kinetics, thermodynamics, and pH dependence of this reaction. The incorporation of
lysozyme
into alpha(2)M* was a mixed bimolecular second-order reaction with a specific rate constant of 91.0 +/- 6.9 m(-1) s(-1), 50.0 degrees C, pH 7.4. The activation energy, activation entropy, and Gibbs' free energy at 50.0 degrees C were 156 kJ mol(-1), 266 J mol(-1) K(-1), and 70 kJ mol(-1), respectively. The rate of incorporation increased as a function of pH from pH 5.0 to 7.0 and was unchanged thereafter. Furthermore, the reaction between alpha(2)M* and
lysozyme
was irreversible. The data are consistent with a two-step mechanism. In the first step, alpha(2)M* reforms its thiol ester bond, entering a reactive state that mimics the proteolytically induced "nascent state." In the rate-limiting second step, the reformed bond quickly undergoes nucleophilic attack by
lysozyme
. The kinetic equations derived in this study are the basis for optimizing the formation of stable alpha(2)M*.antigen complexes.
...
PMID:Kinetics of nonproteolytic incorporation of a protein ligand into thermally activated alpha 2-macroglobulin: evidence for a novel nascent state. 1151 68